MARKET

ASRT

ASRT

Assertio Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.070
+0.077
+7.80%
Closed 19:59 03/02 EST
OPEN
1.010
PREV CLOSE
0.9926
HIGH
1.190
LOW
1.000
VOLUME
24.96M
TURNOVER
--
52 WEEK HIGH
1.450
52 WEEK LOW
0.3300
MARKET CAP
176.31M
P/E (TTM)
-0.4777
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
4 Penny Stocks To Watch Before Tuesday's Opening Bell
Mar 01, 2021 (Penny Stocks via COMTEX) -- Penny Stocks For The Early-March Watch List As March gets off to a great start, investors continue to look for...
Penny Stocks · 1d ago
Assertio Holdings, Inc. to Present at Virtual Roth Conference on Monday, March 15, 2021
Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT) today announced that Dan Peisert, President and Chief Executive Officer of Assertio, will present at and participate in investor meetings at the 33rd Annual Roth Conference, held virtuall...
GlobeNewswire · 1d ago
Maple Leaf Foods Reports Fourth Quarter and Full Year 2020 Financial Results
comExecution against strategic agenda drives further Meat Protein Group Adjusted EBITDA Margin expansion to 12.6%, marking the fifth consecutive quarter of year over year expansion MISSISSAUGA, ON, Feb.
CNW Group · 5d ago
Maple Leaf Foods, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 25, 2021 / Maple Leaf Foods, Inc. (TSX:MFI) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 25, 2021 at 8:00 AM Eastern Time.
ACCESSWIRE · 5d ago
3 Penny Stocks To Buy Under $2 Up Over 100% In 2021
Feb 24, 2021 (Penny Stocks via COMTEX) -- Are These Penny Stocks Still A Buy Right Now? When you think about penny stocks, what comes to mind first? Is it a...
Penny Stocks · 6d ago
Would Shareholders Who Purchased Maple Leaf Foods' (TSE:MFI) Stock Three Years Be Happy With The Share price Today?
As an investor its worth striving to ensure your overall portfolio beats the market average. But in any portfolio...
Simply Wall St. · 02/22 13:48
Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2020 Financial Results After the Close of Markets on Thursday, March 11, 2021
LAKE FOREST, Ill., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it will release fourth quarter and full year 2020 financial results on Thursday, March 11, 2021, after the close ...
GlobeNewswire · 02/18 21:01
Assertio Holdings, Inc. Announces Closing of Registered Direct Offering of $34.3 Million
Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT) today announced that it closed its previously announced registered direct of common stock at a purchase price of $0.98 per share for gross proceeds of approximately $34.3 million.
GlobeNewswire · 02/13 02:32
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ASRT. Analyze the recent business situations of Assertio Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ASRT stock price target is 1.550 with a high estimate of 1.550 and a low estimate of 1.550.
EPS
Institutional Holdings
Institutions: 208
Institutional Holdings: 40.63M
% Owned: 24.66%
Shares Outstanding: 164.77M
TypeInstitutionsShares
Increased
13
3.20M
New
17
-6.13M
Decreased
24
5.57M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.38%
Pharmaceuticals & Medical Research
-0.90%
Key Executives
Chairman/Independent Director
James Fogarty
President/Chief Executive Officer/Director
Arthur Higgins
Chief Financial Officer/Senior Vice President
Daniel Peisert
Senior Vice President/Chief Technology Officer/Chief Scientific Officer
Stanley Bukofzer
Senior Vice President/Director of Human Resources
Sharon Larkin
Independent Director
Karen Dawes
Senior Vice President
Stan Bukofzer
Independent Director
James Galeota
Senior Vice President
Gerd Kochendoerfer
Independent Director
Heather Mason
Independent Director
William McKee
Independent Director
Peter Staple
Independent Director
James Tyree
Independent Director
Gavin Molinelli
Independent Director
David Wheadon
Independent Director
Robert Savage
  • Dividends
  • Splits
  • Insider Activity
No Data
About ASRT
Assertio Holdings, Inc. is a specialty pharmaceutical company. The Company owns a portfolio of prescription neurology, inflammation and pain medications. Its marketed products include Cambia (diclofenac potassium) for Oral solution, INDOCIN Oral Suspension, INDOCIN (indomethacin) Suppositories, OXAYDO tablets, SPRIX Nasal Spray, VIVLODEX capsules, ZIPSOR Liquid filled capsules and ZORVOLEX capsules. The Company is also focused on developing and commercializing neurology, orphan and specialty medicines. Its pipeline products include Diclofenac Potassium, Long-acting Cosyntropin and Diclofenac potassium. Diclofenac Potassium is being developed for mild/moderate acute pain. Long-acting Cosyntropin is being developed for diagnosis of adrenal insufficiency. Diclofenac potassium is a liquid formulation being developed for acute migraine attacks.

Webull offers kinds of Assertio Holdings Inc stock information, including NASDAQ:ASRT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ASRT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ASRT stock methods without spending real money on the virtual paper trading platform.